用于肿瘤代谢显像的几种放射性标记氨基酸

陈立波

用于肿瘤代谢显像的几种放射性标记氨基酸

陈立波

文章导航 > 国际放射医学核医学杂志 > 2002, 26 > 1: (18-20)

引用本文:

Citation:

用于肿瘤代谢显像的几种放射性标记氨基酸

陈立波

200233 上海, 上海第六人民医院核医学科

作者简介: 陈立波(1973-),男,江苏盐城人,住院医师,苏州大学临床核医学硕士研究生,主要研究方向:分子核医学。;

中图分类号: R817.4

The clinical application of radiolabeled amino acids in tumor imaging

CHEN Li-bo

Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China
CLC number: R817.4

摘要: 随着代谢显像的广泛应用,放射性标记氨基酸越来越引起临床关注。与¹⁸F-FDGPET显像相比,氨基酸显像的优点在于其受炎症的影响较小。对于脑肿瘤,氨基酸代谢显像具有较高的诊断价值。对大多数其它类型的肿瘤而言,尽管凭现有资料尚不能得出最终结论,但其总体可行性已得到充分显示。因此,仍有必要进行经过精心设计的更大样本病例的研究。本文着重描述了¹¹C-蛋氨酸(MET)、¹¹C-酪氨酸(TYR)、¹²³I-甲基酪氨酸(IMT)的基本特性和临床应用。
- 放射性标记氨基酸 /
- ¹¹C-蛋氨酸 /
- ¹¹C-酪氨酸 /
- ¹²³I-甲基酪氨酸 /
- 肿瘤显像
Abstract: As the application of metabolic imaging are expanding, radio labeled amino acids may gain increased clinical interest.The fact that amino acid imaging is less influenced by inflammation may be advantageous in comparison with ¹⁸F-FDG PET imaging.In brain tumor, the diagnostic value of amino acid imaging is adequate.In most of other tumors, the data do not yet permit definitive conclusions, but the general feasibility of amino acid imaging has sufficiently been shown.More research is required in larger patient series and in well-defined clinical setting.This review mainly describes the basic aspects and clinical applications of ¹¹C-methionine, ¹¹C-tyrosine, and ¹²³I-iodomethytyrosine.
- radiolabeled amino acids /
- ¹¹C-methionine /
- ¹¹C-tyrosine /
- ¹²³I-iodomethytyrosine /
- tumor imaging
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18] fluoro-alpha-methyl tyrosin:a potential tumor detecting agent[J].J Nuc I Med, 1998,39:663-667.
[2]	Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-¹⁸F] fluoroethyl)-L-tyrosine for tumor imaging[J]. J Nucl Med, 1999, 40:205-212.
[3]	Kubota K, Ishiwata K, Kubota R, et al. Feasibility of fluorine-18-fluotophenyl-alanine for tumor imaging compared with carbon-11-L-methionine[J]. J Nucl Med, 1996,37:320-325.
[4]	Bergstrom M, Lundqvist H, Erieson K, et al. Comparison of the accumulation kinetics of L-methionine in brain tumors studied with positron emission tomography[J].Acta Radiol, 1987, 28:225-229.
[5]	O' Tuama LA, Guilarte TR, Douglass KH, et al. Assessment of[¹¹C]-L-methyionine transport into the human brain[J]. J Cereb Blood Flow Metab, 1988, 8:341-345.
[6]	Roelcke U, Radu E, Ametamey S, et al. Association of rubidium and L-methionine uptake in brain tumors measured by positron emission tomography[J]. J Neurooncol, 1996,27:163-171.
[7]	Souba WW, Pacitti AJ. How animo acids get into cells:mechanism, models, menus and pediators[J].J Parenter Enteral Nutr, 1992, 16:569-578.
[8]	Kubota K, Ishiwata K, Kubota R, et al. Tracer feasibility for monitoring tumor radiotherapy:a quadruple tracer study with or fluorine-18-fluorodeoxyoxyiridine, L-[methyl-¹⁴C] methionine,[6-3H] thymidine, and gallium-67[J]. J Nucl Med, 1991, 32:2118-2123.
[9]	Minn H, Clavo AC, Grenman R,et al.In vivo comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck[J]. J Nucl Med, 1995,36:252-258.
[10]	Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose. L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy[J]. J Nucl Med, 1993, 34:773.
[11]	Schaider H, Haberkom U, Berger MT, et al. Application of alpha-aminoisobutyric acid, L-methionine thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effect of chemotherapy in a human colon carcinoma cell line[J]. Eur J Nucl Med, 1996, 23:55-60.
[12]	Luurtsema G, Medena J, Elsinga PH, et al. Robotic synthesis of L-[¹¹C-tyrosine[J]. Appl Radiat Isot, 1994, 45:Willemsen AT, van Waarde A, Paams AM, et al. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[¹¹C]-tyrosine and PET[J].J Nucl Med, 1995,36:411-419.
[13]	Jager PL, Franssen EJ, Kool W, et al. Feasibility of tumor imaging using L-3-[iodine-123] -iodo-alpha-methyl tyrosine in extracramial tumors[J]. J Nucl Med, 1998, 39:1736-1743.
[14]	Langen KJ, Muhlensipen H, Holschbach M, et al. Trasport mechanisms of 3-123iodo-alpha-methyl-L-tyrosine in a human glioma cell line:comparison with[methyl-³H] -L-methionine[J].J Nucl Med, 2000, 41:1250-1255.
[15]	Riemann B, Stogbauer F, Kopka K, er al. Kinetics of 3-[(123)I]-alpha-methyltyrosine transport in rat C6 glioma cells[J]. Ear J Nucl Med, 1999, 26:1274-1278.
[16]	Deehan B, Carmochan P, Trivedi M, et al. Uptake and distribution of L-3-[iodine-125] -iodo-alpha-methyl tyrosine in experimental rat tumors:comparison with blood flow and growth rate[J]. Eur J Nucl Med, 1993, 20:101-106.
[17]	Jager PL, Plaat BE, Vries de EG. et al. Imaging of soft-tissue tumors using L-3-[iodine-123] iodo-alpha-methyl tyrosine SPECT:comparison with proliferative and mitotic activity, cellularity and vascularity[J]. Clin Cancer Res, 2000,6:2252-2259.
[18]	Heiss P, Mayer S, Hert M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[¹⁸F] fluoroethyl)-L-tyrosine in vivo and in vitro[J]. J Nucl Med, 1999,40:1367-1373.
[19]	Tomiyoshi K, Inoue T, Higuchi T, et al. Metablic studies of[¹⁸F-alpha-methyl] tyrosine in mice bearing colorectal carcinoma LS-180[J]. Anticancer Drugs, 1999:10:329-336.
[20]	Amano S, Inoue T, Tomiyoshi K, et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer[J].J Nucl Med, 1998, 39:1424-1427.
[21]	Orlefors H, Sundin A, Ahlstron H, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors[J]. J Clin Oncol, 1998, 16:2534-2541.
[22]	Wienhard K, Herholz K, Coenen HH, et al. Increased amino acid transport into brain tumors measured by PET of L-(2-¹⁸F)fluorotyrosine[J].J Nucl Med, 1991, 32:1338-1346.
[23]	Ogawa T, Shishido F, Kannl I, et al. Cerebral glioma:evaluation with methionine PET[J]. Radiology, 1993, 186:45-53.

[1]	杨晓诚 , 胡怀湘 , 霍力 . 放射性标记氨基酸的肿瘤基础研究. 国际放射医学核医学杂志, 2003, 27(1): 25-27.
[2]	华逢春 . ¹¹C-METPET在脑肿瘤中的应用. 国际放射医学核医学杂志, 2002, 26(1): 1-4.
[3]	钱忠豪 , 陈可靖 , 闵长庚 . 头颈部癌肿¹⁸F－FDG和¹¹C－蛋氨酸PET显像的对比研究. 国际放射医学核医学杂志, 1994, 18(6): 282-283.
[4]	周惠君 , 董萍 , 沈国华 , 李林 . ¹¹C-蛋氨酸PET/CT显像在脑胶质瘤中的应用价值. 国际放射医学核医学杂志, 2015, 39(2): 161-164. doi: 10.3760/cma.j.issn.1673-4114.2015.02.013
[5]	杨文 , 卢正福 . 用PET研究乳腺癌对¹¹C-蛋氨酸的摄取——与S期分数大小的相关性. 国际放射医学核医学杂志, 1992, 16(6): 283-283.
[6]	李海峰 , 张晓军 , 李云钢 , 沈智辉 , 张锦明 . 国产模块LOOP环改良法合成¹¹C-蛋氨酸. 国际放射医学核医学杂志, 2016, 40(2): 106-110. doi: 10.3760/cma.j.issn.1673-4114.2016.02.004
[7]	杜倩倩 , 陈绍亮 . ¹⁸F-FDG肿瘤显像操作指南. 国际放射医学核医学杂志, 1998, 22(6): 258-260.
[8]	黄俊星 , 王吉欣 , 赵惠杨 . ¹²³I-酪氨酸-澳曲肽显像在小细胞肺癌分期中的作用. 国际放射医学核医学杂志, 1994, 18(3): 139-139.
[9]	胡晓云 , 胡春洪 , 方向明 , 吴翼伟 . 脑胶质瘤的¹¹C-甲硫氨酸和¹¹C-胆碱PET和PET-CT. 国际放射医学核医学杂志, 2008, 32(1): 20-23.
[10]	李林 . ¹⁸F-FDG PET显像在肿瘤学中的应用. 国际放射医学核医学杂志, 2000, 24(6): 254-258.

点击查看大图

计量

文章访问数: 1124
HTML全文浏览量: 142
PDF下载量: 2

用于肿瘤代谢显像的几种放射性标记氨基酸

陈立波

作者简介:陈立波(1973-),男,江苏盐城人,住院医师,苏州大学临床核医学硕士研究生,主要研究方向:分子核医学。

200233 上海, 上海第六人民医院核医学科

收稿日期: 2002-02-06

关键词:

摘要: 随着代谢显像的广泛应用,放射性标记氨基酸越来越引起临床关注。与¹⁸F-FDGPET显像相比,氨基酸显像的优点在于其受炎症的影响较小。对于脑肿瘤,氨基酸代谢显像具有较高的诊断价值。对大多数其它类型的肿瘤而言,尽管凭现有资料尚不能得出最终结论,但其总体可行性已得到充分显示。因此,仍有必要进行经过精心设计的更大样本病例的研究。本文着重描述了¹¹C-蛋氨酸(MET)、¹¹C-酪氨酸(TYR)、¹²³I-甲基酪氨酸(IMT)的基本特性和临床应用。